Business
Establishment Labs to Host Investor Event Featuring Its Motiva Mia System
SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially
About this update from Establishment Labs Holdings Inc.
[{"type":"text","content":" SANTA BARBARA, Calif.--(BUSINESS WIRE)--\nEstablishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it will host a virtual investor event on Feb. 9, 2021 to discuss its Motiva Mia® system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond® breast implant.\n\nThe Motiva Mia system is designed to offer a minimally invasive breast enhancement procedure in less time, with faster recovery and less pain, and without the need for general anesthesia compared to a traditional breast surgery procedure. During the event, members of the Company’s management team will discuss this innovative technology, as well as the potential market opportunity and proposed commercialization timeline. The event will also feature the participation of Charles Randquist, MD; Prof. Marcos Sforza, MD and Jeffry Fassero, MD, who will share their experiences from the recently completed 30-patient Motiva Mia series in the Company’s IRB approved study.\n\nEvent Details\nDate: Tuesday, Feb. 9, 2021\nTime: 1:00 – 2:30 pm EST\nTo register: https://establishmentlabs.zoom.us/webinar/register/WN_55ESTwYRTCKbhtVrzkTzfg\n\nAfter the conclusion of the program, there will be a question and answer session for investors and analysts. A recording of the event will be archived on the Company’s website.\n\nThe Motiva Mia® system is currently not approved for commercial distribution. Motiva Implants® are undergoing clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.\n\nAbout Establishment Labs\n\nEstablishment Labs Holdings Inc. is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigationa...